4-HO-DET Stats & Data
CCN(CC)CCc1cnc2cccc(O)c12OHHYMKDBKJPILO-UHFFFAOYSA-NReceptor Profile
Receptor Actions
Subjective Effects
Physical
- Spontaneous tactile sensations
- Bodily control enhancement
- Increased heart rate
- Nausea
- Pupil dilation
- Tactile enhancement
Cognitive
- Analysis enhancement
- Conceptual thinking
- Delusions
- Emotion enhancement
- Immersion enhancement
- Memory suppression
- Ego death
- Novelty enhancement
- Personal bias suppression
- Thought acceleration
- Thought loops
- Time distortion
- Unity and interconnectedness
- Wakefulness
Sensory
- Enhancements
- Distortions
- Hallucinations
- Drifting: (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- Tracers
- Colour enhancement
- Pattern recognition enhancement
- Visual acuity enhancement
- Transformations
- Internal hallucinations: (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots)
Forked from Subjective Effect Documentation work by Josie Kins, August 2016. Via dose.wiki (CC0).
Toxicity
PsychonautWikiThe toxicity and long-term health effects of recreational 4-HO-DET use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 4-HO-DET is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried 4-HO-DET suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this substance.
Effect Profile
Curated + 11 ReportsStrong visuals, headspace, and auditory effects with strong body load
Duration Timeline
BluelightTolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Too few reports for a chart: gender is known from 18 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?
- Male 14 of 18
- Female 4 of 18
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 11 experience reports (11 single-substance Erowid)
Effect Sentiment Distribution
Confidence Distribution
Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.
Too few reports for bars: these effects come from 11 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
Positive Effects 10
Adverse Effects 3
Show 1 neutral or unclassified mention
Dosage Distribution
Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.
Real-World Dose Distribution
ErowidFrom 19 of 20 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.
Oral (n=18)
Common Combinations
Most co-occurring substances, as a share of all 18 reports filed under 4-HO-DET
Too few reports for bars: these combinations come from 18 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
- THC 6 of 18
Form / Preparation
Most common forms and preparations, as a share of the 12 reports that give one
Too few reports for bars: these forms come from 12 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
- Powder / Crystals 8 of 12
- Capsule 4 of 12
Redose Patterns
Redosing behavior across 13 reports
Too few reports for a chart: redosing is known from 13 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?
- Single dose 13 of 13
- Redosed 0 of 13
Legal Status
| Country | Status | Notes |
|---|---|---|
| Finland | Scheduled in the "government decree on psychoactive substances banned from the consumer market". | |
| Germany | 4-HO-DET is controlled under Anlage I BtMG ( Narcotics Act, Schedule I ), former: Opiumgesetz ( Opium Act ) as of February 25, 1967. | It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license. |
| Sweden | Sveriges riksdags health ministry Statens folkhälsoinstitut classified 4-HO-DET as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Nov 1, 2005, in their regulation SFS 2005:733 listed as 4-hydroxi-N,N-diethyltryptamin (4-HO-DET), making it illegal to sell or possess. | |
| Switzerland | 4-HO-DET is a controlled substance specifically named under Verzeichnis E. | |
| United Kingdom | 4-HO-DET is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause. | |
| United States | 4-HO-DET is unscheduled in the United States, but purchase, sale, or possession for human consumption could be prosecuted under the Federal Analogue Act. |
References
Cited References
- Bluelight: 4-HO-DET Discussion Thread
- Erowid: 4-HO-DET Experience Vaults
- Hofmann A, Troxler F: Therapeutic Indoles for Psychic Stimulation (US Patent 3072530)
- Isomer Design TiHKAL Entry #16: 4-HO-DET
- Leuner H et al: Psycholytische Therapie nach Hanscarl Leuner - Grundlagen, Praxis, Perspektiven
- Talaie H et al: Dose-independent occurrence of seizure with tramadol (2009)